Pathologic, Immunologic, and Clinical Analysis of the Microsatellite Instability Phenotype in Endometrial Carcinoma.
暂无分享,去创建一个
S. Harada | W. Bradley | Mehenaz Hanbazazh | A. Robin | A. C. Mackinnon | R. Summey | C. Johnson | Lyle Christiansen | Darshan Chandrashaker
[1] A. C. Marques,et al. Improved NGS-based detection of microsatellite instability using tumor-only data , 2022, Frontiers in Oncology.
[2] Marieke E. Ijsselsteijn,et al. Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape , 2022, The Journal of pathology.
[3] A. Uguen,et al. Idylla MSI test combined with immunohistochemistry is a valuable and cost effective strategy to search for microsatellite instable tumors of noncolorectal origin , 2022, Pathology international.
[4] A. Tinker,et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study , 2022, Journal for ImmunoTherapy of Cancer.
[5] G. Zannoni,et al. New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines , 2021, Cancers.
[6] T. Buhl,et al. Managing Difficulties of Microsatellite Instability Testing in Endometrial Cancer-Limitations and Advantages of Four Different PCR-Based Approaches , 2021, Cancers.
[7] K. Claes,et al. Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer , 2021, Scientific Reports.
[8] M. Kloor,et al. Implications of Hereditary Origin on the Immune Phenotype of Mismatch Repair-Deficient Cancers: Systematic Literature Review , 2020, Journal of clinical medicine.
[9] L. Insabato,et al. Diagnostic Accuracy of Immunohistochemistry for Mismatch Repair Proteins as Surrogate of Microsatellite Instability Molecular Testing in Endometrial Cancer , 2020, Pathology & Oncology Research.
[10] D. Evans,et al. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer , 2020, Frontiers in Immunology.
[11] Hiroyuki Yamamoto,et al. An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine. , 2019, Seminars in oncology.
[12] M. Frey,et al. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? , 2019, Cancer.
[13] P. Keegan,et al. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors , 2019, Clinical Cancer Research.
[14] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[15] Marc J. Williams,et al. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response , 2018, The Journal of pathology.
[16] S. Kyo,et al. Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer , 2017, Oncotarget.
[17] N. Chaput,et al. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. , 2017, European journal of cancer.
[18] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[19] S. Mok,et al. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters , 2017, Clinical Cancer Research.
[20] H. Morreau,et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] R. Eisenberg,et al. Differences in Microsatellite Instability Profiles between Endometrioid and Colorectal Cancers: A Potential Cause for False-Negative Results? , 2017, The Journal of molecular diagnostics : JMD.
[22] D. Tritchler,et al. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Lauren L. Ritterhouse,et al. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. , 2015, JAMA oncology.
[24] F. Gao,et al. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] P. Klenerman,et al. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer , 2015, Clinical Cancer Research.
[26] H. Mackay,et al. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing , 2014, Cancer.
[27] B. Melichar,et al. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in patients with endometrial carcinoma. , 2014, Anticancer research.
[28] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[29] T. Smyrk,et al. Tumor‐infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma , 2001, Cancer.